Innoviva, Inc. INVA External Services — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Innoviva, Inc.'s external services — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Innoviva, Inc.'s external services — research and development expense?
- Innoviva, Inc. (INVA) reported external services — research and development expense of $2.61M in Q1 2026.
- How has Innoviva, Inc.'s external services — research and development expense changed year-over-year?
- Innoviva, Inc.'s external services — research and development expense decreased by 14.6% year-over-year, from $3.05M to $2.61M.
- What is the long-term trend for Innoviva, Inc.'s external services — research and development expense?
- Over 3 years (2022 to 2025), Innoviva, Inc.'s external services — research and development expense has grown at a -14.0% compound annual growth rate (CAGR), from $24.67M to $15.71M.
- What does external services — research and development expense mean?
- This metric represents the total costs incurred by the External Services segment for research and development activities, including clinical trials, product development, and scientific innovation efforts. It reflects the company's investment in advancing its healthcare asset pipeline and maintaining the competitive viability of its specialized service offerings. Monitoring this expense helps investors assess the segment's commitment to long-term growth and its capacity to innovate within the critical care and infectious disease markets.